Literature DB >> 34150073

LncRNA GAS5 expression in non-small cell lung cancer tissues and its correlation with Ki67 and EGFR.

Yihui Fu1, Lirong Liu1, Jiabin Zhan2, Huijuan Zhan3, Chun Qiu4.   

Abstract

OBJECTIVE: This research explored and analyzed LncRNA GAS5 expression in non-small cell lung cancer (NSCLC) tissues and its correlation with Ki67 and EGFR.
METHODS: A total of 130 samples of paraffin-embedded NSCLC tissues and para-cancerous normal tissues that were collected in the Department of Pathology from January 2014 to April 2016 were selected. The relative expression of LncRNA GAS5 and Ki67/EGFR in both NSCLC tissues and para-cancerous normal tissues were detected via RT-PCR and immunohistochemistry respectively. Subsequently, we analyzed the relative expression of LncRNA GAS5, the expression of Ki67/EGFR and its correlation with clinicopathological features and prognosis of patients, and studied the correlation between LncRNA GAS5 and Ki67/EGFR.
RESULTS: The relative expression of LncRNA GAS5 in NSCLC tissues was substantially less than that of the para-cancerous normal tissues (P<0.05). The positive expression rate of Ki67/EGFR in NSCLC tissues remarkably exceeded that in para-cancerous normal tissues (P<0.05). The relative expression of LncRNA GAS5 was correlated with the degree of tumor differentiation, TNM staging and lymph node metastasis (P<0.05). The positive expression rate of Ki67 and EGFR in NSCLC tissues was related to TNM stage and metastasis of lymph node (P<0.05). In addition, the survival of patients with high LncRNA GAS5 expression was obviously superior to those with low LncRNA GAS5 expression (P<0.05), patients with negative Ki67 had superior survival than those with positive Ki67 (P<0.05), and patients with negative EGFR had increased survival over those with positive EGFR (P<0.05). Moreover, the positive rates of Ki67 and EGFR in patients with low LncRNA GAS5 expressions were obviously higher than those with high LncRNA GAS5 expressions (P<0.05). The relative expression level of LncRNA GAS5 in NSCLC patients had a remarkably negative correlation with Ki67 and EGFR (P<0.05).
CONCLUSION: The decrease in LncRNA GAS5 expression and the over-express of Ki67/EGFR occur in NSCLC tissues, the expressions of LncRNA GAS5, Ki67 and EGFR are connected with the progression, metastasis and prognosis of tumor; and LncRNA GAS5 is related to the expression of Ki67 and EGFR. These three factors are involved in the tumorigenesis and growth of the NSCLC process. AJTR
Copyright © 2021.

Entities:  

Keywords:  EGFR; Ki67; LncRNA GAS5; Non-small cell lung cancer

Year:  2021        PMID: 34150073      PMCID: PMC8205762     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  25 in total

1.  TINCR facilitates non-small cell lung cancer progression through BRAF-activated MAPK pathway.

Authors:  Zhi-Jun Zhu; Jing-Kang He
Journal:  Biochem Biophys Res Commun       Date:  2018-02-07       Impact factor: 3.575

2.  LncRNA TUC338 promotes invasion of lung cancer by activating MAPK pathway.

Authors:  Y-X Zhang; J Yuan; Z-M Gao; Z-G Zhang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2018-01       Impact factor: 3.507

3.  LncRNA GASL1 inhibits tumor growth of non-small cell lung cancer by inactivating TGF-β pathway.

Authors:  W-Z Su; X Yuan
Journal:  Eur Rev Med Pharmacol Sci       Date:  2018-11       Impact factor: 3.507

4.  LncRNA FBXL19-AS1 promotes proliferation and metastasis via regulating epithelial-mesenchymal transition in non-small cell lung cancer.

Authors:  D-J Yu; Y-H Li; M Zhong
Journal:  Eur Rev Med Pharmacol Sci       Date:  2019-06       Impact factor: 3.507

5.  lncRNA HNF1A-AS1 modulates non-small cell lung cancer progression by targeting miR-149-5p/Cdk6.

Authors:  Lu Liu; Yanzhi Chen; Qiaoqing Li; Peizeng Duan
Journal:  J Cell Biochem       Date:  2019-06-26       Impact factor: 4.429

6.  LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.

Authors:  Y Cai; Z-Y Dong; J-Y Wang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2018-08       Impact factor: 3.507

7.  Long non-coding RNA TUG1 is involved in cell growth and chemoresistance of small cell lung cancer by regulating LIMK2b via EZH2.

Authors:  Yuchun Niu; Feng Ma; Weimei Huang; Shun Fang; Man Li; Ting Wei; Linlang Guo
Journal:  Mol Cancer       Date:  2017-01-09       Impact factor: 27.401

8.  SNPs in LncRNA genes are associated with non-small cell lung cancer in a Chinese population.

Authors:  Ruoyang Wang; Nannan Feng; Yu Wang; Sumeng Gao; Fangfang Zhang; Ying Qian; Ming Gao; Herbert Yu; Baosen Zhou; Biyun Qian
Journal:  J Clin Lab Anal       Date:  2019-04-13       Impact factor: 2.352

9.  A seven-long noncoding RNA signature predicts overall survival for patients with early stage non-small cell lung cancer.

Authors:  Ting Lin; Yunong Fu; Xing Zhang; Jingxian Gu; Xiaohua Ma; Runchen Miao; Xiaohong Xiang; Wenquan Niu; Kai Qu; Chang Liu; Qifei Wu
Journal:  Aging (Albany NY)       Date:  2018-09-11       Impact factor: 5.682

View more
  1 in total

1.  Long non‑coding RNA LINC01748 exerts carcinogenic effects in non‑small cell lung cancer cell lines by regulating the microRNA‑520a‑5p/HMGA1 axis.

Authors:  Yinling Tan; Fengxia Xu; Lingling Xu; Jianying Cui
Journal:  Int J Mol Med       Date:  2021-12-31       Impact factor: 4.101

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.